Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 30, 2010 Cliff D'Arcy	Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline.
The Motley Fool February 1, 2008 Brian Lawler	AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs.
The Motley Fool April 24, 2007 Brian Lawler	MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal.
The Motley Fool April 28, 2008 Brian Lawler	Glaxo Getting By Weakening currency barely redeems the pharmaceutical's Q1 numbers.
The Motley Fool October 14, 2010 Sean Williams	Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away.
The Motley Fool February 28, 2011 Brian Orelli	Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out?
The Motley Fool April 15, 2011 Brian Orelli	Shedding the Pounds Through Divestiture Glaxo plans to sell 19 OTC products.
The Motley Fool October 30, 2008 Brian Orelli	What's on Deck for AstraZeneca? The drugmaker increases EPS by cutting costs, but it's the next move that will count the most.
The Motley Fool April 26, 2007 Brian Lawler	AstraZeneca's Announcement Overshadows Earnings AstraZeneca releases first-quarter financial results. Investors, take note.
The Motley Fool April 12, 2011 Brian Orelli	Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets.
The Motley Fool February 8, 2008 Brian Lawler	Hold on to GlaxoSmithKline This might be a tough year for the big pharma company, but its pipeline makes it a keeper.
The Motley Fool April 29, 2011 Brian Orelli	Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves.
The Motley Fool July 25, 2008 Brian Lawler	Glaxo Changes Course Will a shift in strategy turn the drugmaker around?
The Motley Fool July 27, 2006 Stephen D. Simpson	AstraZeneca Needs a Rest The stock isn't too expensive, but it's no longer a bargain.
The Motley Fool April 27, 2006 Stephen D. Simpson	Glaxo's Story Still Worth Reading A good pipeline could keep GlaxoSmithKline's already-impressive shares rolling.
The Motley Fool November 30, 2009 Brian Orelli	Making Money More Efficiently Drug companies shape up, and it shows in their margins.
The Motley Fool May 21, 2009 Robert Steyer	The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations?
The Motley Fool June 25, 2011 Jordan DiPietro	Should You Buy and Hold AstraZeneca? AstraZeneca has a beta of 0.3, which is pretty low. Generally speaking, I like to see a beta below 1.2 for retirees, and AstraZeneca fits the bill.
The Motley Fool December 4, 2007 Brian Lawler	Another Drug Deal Goes Down Canadian specialty pharma Axcan Pharma became the latest drugmaker to be acquired by a private equity group -- for $1.3 billion in cash.
The Motley Fool February 3, 2011 Owain Bennallack	Glaxo Sweetens a Bitter Pill The drugmaker reports a loss, but resumes share buybacks.
The Motley Fool November 2, 2011 Prabhat Sakya	AstraZeneca vs. GlaxoSmithKline If you could only invest in one of these companies, which would it be?
The Motley Fool October 21, 2008 Brian Orelli	The World Is Saving Pfizer The pharma company experienced a double-digit decrease in U.S. sales in the third quarter. Ouch.
The Motley Fool March 29, 2010 Brian Orelli	5 Drugmakers Producing Cash for You Take greenbacks over earnings any day.
The Motley Fool April 27, 2006 Stephen D. Simpson	Investors Get Starry-Eyed for AstraZeneca Investors, while this British drug giant is getting its due from the market now in response to strong earnings, positive guidance, and more confidence in the future portfolio of drugs, remember to do your own due diligence first.
Chemistry World February 2, 2012 Andrew Turley	AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term.
Chemistry World December 20, 2013 Patrick Walter	AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
Chemistry World December 24, 2015 Jennifer Newton	AstraZeneca to buy Acerta for blood cancer drug AstraZeneca has agreed to buy a majority stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US.
BusinessWeek November 14, 2005 Gene G. Marcial	Rivals Are Eyeing Wyeth Drugmaker Wyeth is the most attractive in the beleaguered pharma sector.
The Motley Fool August 27, 2010 Jordan DiPietro	AstraZeneca's Dividends May Not Last Forever AstraZeneca's payout ratio compared to its peers is a lower percentage, which illustrates that its dividend is probably more sustainable.
The Motley Fool February 2, 2006 Stephen D. Simpson	AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here.
The Motley Fool January 31, 2007 Brian Lawler	Lilly Floats Atop Rivals The large-cap pharma posts slow, steady growth. Investors, take note.
Pharmaceutical Executive January 1, 2011 Walter Armstrong	The List It's a new year. Even pharma, with its glacial timelines, has its "Out with the old, in with the new" moment. Welcome to 2011!
Chemistry World April 24, 2007 Victoria Gill	AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune.
The Motley Fool January 27, 2011 Brian Orelli	Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out.
The Motley Fool November 3, 2009 Brian Orelli	A Little Distracted, Are You, Merck? The FDA rejects its latest application.
The Motley Fool December 13, 2011 Brian Orelli	Dividend? Buyback? Here's How to Get Both. But will there be enough to replenish the pipeline?
The Motley Fool October 30, 2009 Brian Orelli	Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future.
The Motley Fool April 30, 2010 Brian Orelli	Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter.
The Motley Fool October 30, 2010 Anand Chokkavelu	7 Pharma Stocks Near 52-Week Highs Here are the top seven companies in the pharmaceutical space (by market cap) that are within spitting distance of their 52-week highs: J&J... Novartis... Merck... GlaxoSmithKline... Abbott... AstraZeneca... Novo Nordisk...
The Motley Fool August 10, 2010 Todd Wenning	Dividend Report Card: AstraZeneca Does this drugmaker's dividend pass the test?
The Motley Fool September 30, 2008 Brian Lawler	Moody's Gets Moody With Drugmakers European pharmaceuticals get a negative rating from Moody's.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool July 26, 2006 Stephen D. Simpson	GlaxoSmithKline: Reliable, Dependable ... Kinda Boring This is a good-but-not-great pharmaceutical giant with a good-but-not-great valuation. Investors, take note.
The Motley Fool January 8, 2010 Brian Orelli	Heartburn Relieved ... for Now AstraZeneca settles its patent dispute with Teva.
The Motley Fool December 21, 2010 Brian Orelli	4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday.
BusinessWeek December 29, 2010 Kelley & Cortez	AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs.
Chemistry World April 29, 2014 Phillip Broadwith	Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion.
The Motley Fool January 28, 2008 Brian Lawler	A Great Way to Recession-Proof Your Portfolio If you want a recession resistant portfolio, invest in large cap pharmaceuticals.
Chemistry World January 28, 2010 Nina Notman	AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost.